Gene · 4507
Papers2,281
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1 to 20 of 2,281
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| MTAP loss upregulates BCAT1 in pancreatic cancer and drives branched-chain amino acid dependency. | Cell Rep | 2026 | 42814576 | PubTator, text mining | PubMed |
| Genomic Landscape of Primary and Secondary Cutaneous Angiosarcoma: A Single-Center Retrospective Cohort Analysis in Japan. | J Dermatol | 2026 | 42810841 | PubTator, text mining | PubMed |
| Digital PCR for Detecting Loss of BAP1 and MTAP in Pleural Fluids of Mesothelioma Patients: Perspectives in the Diagnosis. | Pathol Int | 2026 | 42801547 | PubTator, text mining | PubMed |
| Contemporary Landscape of Active Clinical Trials in Pancreatic Ductal Adenocarcinoma: A ClinicalTrials.gov-Based Narrative Review with a Scoping Approach. | Pharmaceuticals (Basel) | 2026 | 42797417 | PubTator, text mining | PubMed |
| Metabolomics and Machine Learning Uncover 5'-Methylthioadenosine as a Metabolic Indicator of Mixed-Pattern Drug-Induced Liver Injury. | Metabolites | 2026 | 42783739 | PubTator, text mining | PubMed |
| Interrupted surveillance and delayed genetic evaluation in neurofibromatosis type 1 associated with advanced malignant peripheral nerve sheath tumor and breast cancer: A case report. | Int Cancer Conf J | 2026 | 42781021 | PubTator, text mining | PubMed |
| Immunohistochemistry Resolves Indeterminate MTAP Deletion Calls From Exome Sequencing: A Pan-Cancer Concordance Study. | Mod Pathol | 2026 | 42778110 | PubTator, text mining | PubMed |
| CDKN2A/B status can be assessed by p16/MTAP immunohistochemistry as a practical surrogate in pleomorphic xanthoastrocytoma and high-grade astrocytoma with piloid features. | J Neuropathol Exp Neurol | 2026 | 42777114 | PubTator, text mining | PubMed |
| Catalytical nanogels reprogram immunosuppressive metabolic networks for activatable cancer photo-immunotherapy. | J Control Release | 2026 | 42767374 | PubTator, text mining | PubMed |
| Low frequency of MTAP co-deletion with CDKN2A in peritoneal mesothelioma suggests an independent diagnostic role for MTAP. | Histopathology | 2026 | 42766860 | PubTator, text mining | PubMed |
| Emerging therapeutic strategies and clinical development of investigational agents for conventional chondrosarcoma. | Expert Opin Investig Drugs | 2026 | 42757818 | PubTator, text mining | PubMed |
| Case Report: Metachronous oncocytic and colloid carcinoma arising from pancreatic intraductal neoplasms over four decades. | Front Oncol | 2026 | 42755625 | PubTator, text mining | PubMed |
| Clinicopathologic and Molecular Insights Into ERBB2-Altered S100/SOX10-Positive Uterine Sarcoma: A Report of 6 Cases. | Mod Pathol | 2026 | 42754232 | PubTator, text mining | PubMed |
| Lessons from Cohort Studies of Targetable Metabolic Deficiencies in Lung Cancer. | Clin Cancer Res | 2026 | 42726138 | PubTator, text mining | PubMed |
| Case Report: Targeting EGFR exon 20 insertion and MTAP loss in refractory metastatic upper tract urothelial carcinoma. | Front Oncol | 2026 | 42723945 | PubTator, text mining | PubMed |
| Camrelizumab plus nimotuzumab as second-line therapy for advanced esophageal squamous cell carcinoma: a multicenter phase II study. | J Immunother Cancer | 2026 | 42711069 | PubTator, text mining | PubMed |
| Targeted therapies in advanced non-small-cell lung cancer: new biomarkers and treatment strategies. | Lancet Respir Med | 2026 | 42702211 | PubTator, text mining | PubMed |
| Prognostic Markers in Meningioma: Effectiveness of FISH-Assessed CDKN2A/B Homozygous Deletion and Limits of Surrogate p16/MTAP Immunohistochemistry in Predicting Disease-Specific Survival. | Neuropathol Appl Neurobiol | 2026 | 42699993 | PubTator, text mining | PubMed |
| MTAP loss in non-small-cell lung Cancer and beyond: Therapeutic targeting of the MAT2A-PRMT5 axis. | Cancer Treat Rev | 2026 | 42685449 | PubTator, text mining | PubMed |
| Multi-omics integration in malignant pleural mesothelioma: from molecular evolution and immune ecosystems to precision therapy. | Front Oncol | 2026 | 42676823 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4507/papers